The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RCKT | -79.42% | -90.46% | -37.46% | -76% |
| S&P | +13.19% | +87.83% | +13.42% | +145% |
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Its near-term risks are subtle but bigger than their flying stock price might indicate.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$3.24M | -35.6% |
| Market Cap | $351.77M | -79.1% |
| Market Cap / Employee | $1.18M | 0.0% |
| Employees | 299 | 11.6% |
| Net Income | -$50.33M | 24.6% |
| EBITDA | -$49.18M | 26.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $75.95M | 15.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $22.13M | -2.9% |
| Short Term Debt | $2.91M | 2.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.25% | -11.2% |
| Return On Invested Capital | -41.02% | -6.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$50.37M | 6.2% |
| Operating Free Cash Flow | -$50.43M | 3.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.47 | 1.53 | 0.63 | 0.99 | -77.27% |
| Price to Tangible Book Value | 4.31 | 1.78 | 0.75 | 1.21 | -76.87% |
| Enterprise Value to EBITDA | -14.57 | -7.19 | -0.39 | -3.38 | -85.20% |
| Return on Equity | -54.1% | -60.5% | -69.6% | -74.9% | 26.34% |
| Total Debt | $25.50M | $25.35M | $25.20M | $25.05M | -2.33% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
